Jennifer Chao Quotes (3 Quotes)

Vaccines are beginning to be viewed as a much more attractive business compared to five years ago.

We anticipate Amgen to serve Roche an official court summons towards 306 timeframe upon which Roche will respond and the patent litigation suit will be in process. Ultimately, we continue to believe that Amgen will successfully defend its erythropoietin patents and that CERA will be found to have infringed.

One of Chiron's issues is it really never had a strong identify with the biotech investing community.